Search

456 Result(s)
Sort by

Clinical-phase2-trials-NASH-and-obesity

Clinical-phase2-trials-NASH-and-obesity

Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
sustainably fighting rabies info hub

sustainably fighting rabies info hub

Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.
emperor-preserved-chmp-positive-opinion

emperor-preserved-chmp-positive-opinion

CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
Disentangling fibrosis

Disentangling fibrosis

Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
FDA-CRL-T1D

FDA-CRL-T1D

US FDA issues complete response letter for treatment of adults with type 1 diabetes
BI Access to Healthcare Strategy_Availability

BI Access to Healthcare Strategy_Availability

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Anna Race

Anna Race

Anna Race, Sales Director, Human Pharma, UK & Ireland, tells us how a career in our Commercial Division helps her to make a difference.
CAROLINA-CARMELINA-Asia-analysis

CAROLINA-CARMELINA-Asia-analysis

CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes
Collaboration to fight NCDs

Collaboration to fight NCDs

70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.